Session 3 - Castration-sensitive prostate cancer
Rising PSA and detectable PSA after radical local treatment: Prognosis, indications for salvage local treatments, adjuvant vs salvage treatments
Date
28 Oct 2021Session
Session 3 - Castration-sensitive prostate cancerPresenters
A. Bossi, FRResources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
Use of early vs deferred systemic treatments in biochemical failures and in M0 CRPC
Presenter: K. Fizazi, FR
Session: Session 3 - Castration-sensitive prostate cancer
Resources:
Slides
Webcast
Metastatic castration-sensitive prostate cancer (mCSPC)
Presenter: S. Gillessen, CH
Session: Session 3 - Castration-sensitive prostate cancer
Resources:
Slides
Webcast
Oligo-metastatic treatment: what treatment?
Presenter: A. Bossi, FR
Session: Session 3 - Castration-sensitive prostate cancer
Resources:
Slides
Webcast
Participant Clinical Case Discussion: A case of Docetaxel vs Enzalutamide
Presenter: H. Dearden, UK
Session: Session 3 - Castration-sensitive prostate cancer
Resources:
Slides
Webcast